Category Archives: Mesenchymal Stem Cells

(Phys.org) -- New research at the Hebrew University of Jerusalem sheds light on pluripotencythe ability of embryonic stem cells to renew themselves indefinitely and to differentiate into all types of mature cells. Solving this problem, which is a major challenge in modern biology, could expedite the use of embryonic stem cells in cell therapy and regenerative medicine. If scientists can replicate the mechanisms that make pluripotency possible, they could create cells in the laboratory which could be implanted in humans to cure diseases characterized by cell death, such as Alzheimer's, Parkinson's, diabetes and other degenerative diseases. To shed light on these processes, researchers in the lab of Dr. Eran Meshorer, in the Department of Genetics at the Hebrew Universitys Alexander Silberman Institute of Life Sciences, are combining molecular, microscopic and genomic approaches. Meshorer's team is focusing on epigenetic pathwayswhich cause biological changes without a corresponding change in the DNA sequencethat are specific to embryonic stem cells. The molecular basis for epigenetic mechanisms is chromatin, which is comprised of a cell's DNA and structural and regulatory proteins. In groundbreaking research performed by Shai Melcer, a PhD student in the Meshorer lab, the mechanisms which support an open chromatin conformation in embryonic … Continue reading →

LEUVEN, BELGIUM--(Marketwire -07/17/12)- TiGenix (EURONEXT:TIG), the European leader in cell therapy, announced today that after obtaining national reimbursement for ChondroCelect in the Netherlands last month, the company has now contracted with four major hospitals to make its innovative cartilage repair therapy available to their patients on a routine basis: University Medical Center Utrecht, University Hospital Maastricht, Martini Hospital Groningen, and, most recently, the Elisabeth Hospital Tilburg. Discussions with other Cartilage Expert Centers are ongoing. Reimbursement for ChondroCelect in the Netherlands is retroactive per January 1, 2011. "Our close collaboration with the Dutch hospitals is key to making ChondroCelect available to patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch scientists and clinicians have made important contributions to the development of this innovative cartilage repair therapy. Patients who suffer from cartilage lesions in the knee that cause recurrent pain and can be incapacitating can now be routinely treated and literally find their footing again. We expect to soon expand the number of hospitals in the Netherlands where ChondroCelect is available." Damage to the articular cartilage in the knee can be caused by sports or professional activities in which the knee is repeatedly and forcefully impacted. It is a condition … Continue reading →

REHOVOT, Israel and PARIS - BioView Ltd. (TASE: BIOV) and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit. Dr. Alan Schwebel, President and CEO of BioView, views this agreement as a unique combination of two innovative technologies, one designed by ScreenCell to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection. "BioView's unique automated imaging and analysis solutions for the detection and of rare cells greatly enhance research and clinical laboratory productivity and assay development process. We are proud to be ScreenCell's global partner and look forward to expanding our relationship." Bioview's Imaging Systems are designed to accommodate both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells. Utilizing field-proven algorithms developed and perfected in collaboration with leading cancer research centers worldwide, BioView's scanning platform is the ideal solution for both clinical and research laboratories wishing to enhance their productivity and assay development processes. ScreenCell offers innovative, single-use devices to … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR) announced today that the company has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to submit a full proposal for a Broad Agency Announcement (BAA) to fund advanced research and development of countermeasures, specifically in the area of mass casualty thermal burn injuries. The companys Biosurgery product, Grafix, was the focus of a submission to BARDA in early March. BARDA carefully reviewed white papers it received in response to the BAA in order to select definitive care products acceptable for submission of a full proposal. BARDA is seeking safe and effective medical products that can be used to treat a wide range of types of burn injuries, resulting from any cause, and importantly from any mass-casualty incident. Grafix is currently used at burn centers across the country to treat thermal burns of differing thicknesses in both pediatric and adult patients. To most effectively address the governments needs in mass casualty situations, Osiris research-based proposal to BARDA will focus on additional clinical development and large scale manufacturing. About BARDA The Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department … Continue reading →

Sugarland cosmetic dentist Dr. Jue from A Beautiful Smile at Lake Pointe becomes the first provider of dental stem cell therapy in Fort Bend County through Store-A-Tooth. Sugarland, TEXAS (PRWEB) July 10, 2012 Sugarland cosmetic dentist Dr. Lance Jue from A Beautiful Smile at Lake Pointe has become the first provider of dental stem cell therapy in Fort Bend County. Dental stem cell therapy saves stem cells from baby teeth, teeth removed for orthodontic reasons and wisdom teeth to help with future infections, injuries or diseases. Dr. Jue works with Store-A-Tooth, which provides a Tooth Transport Kit, collects and validates the stems cells that are collected from the tooth. The cells are kept frozen until the day they are needed, at which time they are sent to the patients healthcare provider. Dental stem cells have been used to treat periodontal disease, diabetes, spinal cord injury, stroke and liver disease. Stem cells are different from other cells because they can transform into many different cell types and divide more than other types of cells. Dental stem cells are particularly effective because they replicate faster than stem cells take from other body tissues. The initial cost of the Store-A-Tooth service is one-third … Continue reading →

Public release date: 11-Jul-2012 [ | E-mail | Share ] Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (July 11, 2012) A research team in the Netherlands has found that cells from burn eschar, the non-viable tissue remaining after burn injury and normally removed to prevent infection, can be a source of mesenchymal cells that may be used for tissue engineering. Their study compared the efficacy of those cells to adipose (fat)-derived stem cells and dermal fibroblasts in conforming to multipotent mesenchymal stromal cell (MSC) criteria. Their study is published in the current issue of Cell Transplantation (21:5), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/. "In this study we used mouse models to investigate whether eschar-derived cells fulfill all the criteria for multipotent mesenchymal stromal cells as formulated by the International Society for Cellular Therapy (ISCT)," said study co-author Dr. Magda M.W. Ulrich of the Association of Dutch Burn Centres, The Netherlands. "The study also assessed the differentiation potential of MSCs isolated from normal skin tissue and adipose tissue and compared them to cells derived from burn eschar." According to the researchers, advances in burn treatment have meant that the percentage of … Continue reading →

Mesoblast (MSB.AX) (OTC:MEOBF) CEO Silviu Itesu speaks on his company`s adult stem cell technology, particularly mesenchymal precursor cells, and the low-cost manufacturing capabilities that the technology implies. Itesu discusses development compound Revascor for use in congestive heart failure and details the latest Phase II results. In 60 patients the drug saw no adverse events and a 0% event rate (hospital visits, mortality) compared to 20% in a control group; the company is planning to initiate a 1500-patient Phase III study in the coming few months. The trials are funded entirely by Teva (TEVA), says Itesu, but the company`s financial situation would allow for a few years of `solo` operation. Itesu briefly compares Mesoblast`s production strategies to those of Dendreon`s (DNDN) Provenge, and explains how Mesoblast`s production will be significantly less expensive. The conversation also covers two more pipeline products, a Type-2 diabetes treatment and an intervertebral disc treatment, both of which have shown promising results in Phase II studies. Click Here to view our video interview of Mesoblast CEO Silviu Itesu. About PropThink PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and … Continue reading →

Tuloy na ang stem cell therapy ni Annabelle Rama dahil naka-schedule na siyang pumunta sa Germany sa first week ng September. Kasama ni Annabelle sa Germany trip ang kanyang anak na si Ruffa Gutierrez. Hindi ako sure kung may plano rin si Ruffa na magpa-stem cell therapy dahil walang age limit ang procedure na pinag-uusapan na ngayon sa apat na sulok ng showbiz. Tinutukso si Annabelle Rama na may kinalaman sa kanyang pagkandidato sa Cebu ang desisyon niya na sumailalim sa stem cell therapy. Tumawa lang si Bisaya na mukhang seryoso na sa pagkandidato bilang kongresista ng North Cebu sa eleksiyon sa susunod na taon. Binibiro si Bisaya na magpapa-stem cell therapy siya para kundisyon na kundisyon ang katawan niya habang nangangampanya sa North Cebu. Ayaw kumpirmahin ni Bisaya ang political plans niya. Hintayin na lamang daw ng mga tao ang kanyang bonggang announcement sa October. Asawa ni Jose nag-iba ng abogado matapos matalo How true na iba na raw ang lawyers ni Analyn Manalo kaya tumanggi nang magsalita ang kanyang mga dating abogado? Si Analyn ang kontrobersiyal na dyowa ni Jose Manalo. Ilang buwan nang nasa news ang mag-asawa dahil sa kanilang paghihiwalay. News noong weekend na natalo si … Continue reading →

NEW YORK, July 10, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that its CEO will present at the Seventh Annual JMP Securities Healthcare Conference on July 12, 2012. The presentation will be webcast live and available to view at the following web address: http://wsw.com/webcast/jmp18/nbs/. The webcast will be archived for 90 days following the live presentation. The Seventh Annual JMP Securities Healthcare Conference About NeoStem, Inc. NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing … Continue reading →

Regulated information July 10, 2012 TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas ADMIRE CD trial to enroll over 200 patients in 46 centers across 8 countries Leuven (BELGIUM) - July 10, 2012 - TiGenix (NYSE Euronext: TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn`s disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn`s disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn`s disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & … Continue reading →